Samrotamab, also known as LCL100, represents a significant advance in cancer study. This innovative clonal protein is currently in development evaluation and demonstrates encouraging potential for targeting specific https://ztndz.com/story28144960/samrotamab-a-promising-targeted-antibody-in-progress